Skip to Content
Merck
  • Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions.

Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions.

Bioorganic & medicinal chemistry (2013-01-12)
Tino Wilson Sanchez, Bikash Debnath, Frauke Christ, Hiroyuki Otake, Zeger Debyser, Nouri Neamati
ABSTRACT

Human lens epithelium-derived growth factor (LEDGF)/p75 plays an important role in the HIV life cycle by stimulating integrase (IN)-led viral DNA integration into cellular chromosomes. Mechanistic studies show the majority of IN inhibitors chelate magnesium ions in the catalytic active site, a region topologically distant from the LEDGF/p75 binding site. Compounds disrupting the formation of LEDGF/p75 and IN complexes serve as a novel mechanistic approach different from current antiretroviral therapies. We previously built pharmacophore models mimicking LEDGF/p75 residues and identified four classes of LEDGF/p75-IN inhibitors. Substructure and similarity searches yielded additional LEDGF/p75-IN inhibitors containing an acylhydrazone moiety. The most potent of the acylhydrazones inhibited LEDGF/p75-IN interaction with an IC(50) value of 400nM. We explored structure-activity relationships (SAR) and identified new acylhydrazones, hydrazines, and diazenes as lead molecules for further optimization. Two lead LEDGF/p75-IN inhibitors showed antiviral activity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrazine sulfate salt, ACS reagent, ≥99.0%
Sigma-Aldrich
Hydrazine monohydrate, N2H4 64-65 %, reagent grade, ≥97%